Debio 0932 NEW
| Price | $64 |
| Package | 2mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-11 |
Product Details
| Product Name: Debio 0932 | CAS No.: 1061318-81-7 |
| Purity: 98.98% | Supply Ability: 10g |
| Release date: 2026/05/11 |
Product Introduction
Bioactivity
| Name | Debio 0932 |
| Description | Debio 0932 (CUDC-305) is a heat shock protein 90 (Hsp90) inhibitor that targets the n-terminal atp-binding pocket to promote apoptosis, and has the advantage of being orally available and able to cross the blood-brain barrier (BBB) for the treatment of cancers such as non-small-cell lung cancer (NSCLC) and neuroblastoma. |
| In vitro | Debio 0932 exhibits dose- and time-dependent proliferation inhibition in MCF-7 and MDA-MB-231 cells, with IC50 values of 6.19 μM and 10.66 μM at 48 hours, respectively. It promotes apoptosis by upregulating Bax/Bcl-2, activating Caspase-9, and inhibiting HUVEC migration [1]. In NSCLC, the IC50 values against A549, H1299, and H1975 cells are 3.26±2.82 μM, 20.33±5.39 μM, and 3.16±1.04 μM, respectively. It induces cell cycle arrest and apoptosis, and targets Hsp90 with an IC50 value of 70 nmol/L, leading to the degradation of mutant EGFR and K-RAS, thus reversing erlotinib resistance [2,3]. |
| In vivo | In a psoriasis xenograft model, treatment with Debio 0932 (80 mg/kg, orally daily) for 3 weeks resulted in a significant clinical improvement by day 11, with a marked reduction in epidermal thickness [4]. In the U87MG glioblastoma mouse model, treatment with Debio 0932 (160 mg/kg, every other day) induced tumor regression. In an acute myeloid leukemia (AML) mouse model, after 3 weeks of treatment with Debio 0932 (160 mg/kg, every other day), complete tumor regression was observed, with good drug safety [5]. |
| Storage | Store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (4.52 mM), Sonication is recommended. DMSO : 60 mg/mL (135.57 mM), Sonication is recommended. |
| Keywords | HSP90β | HSP90α | Debio 0932 | CUDC 305 |
| Inhibitors Related | Ethoxyquin | Adezmapimod | Tamoxifen | Palmitic acid sodium | Mequinol | 7-Aminocephalosporanic acid | Benzbromarone | Elesclomol | Rifabutin | Palmitic acid | Tamoxifen Citrate | Isoxazole |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $96.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-06-02 | |
| $1520.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-04-20 | |
| $9.80 |
VIP7Y
|
Career Henan Chemical Co
|
2020-01-03 | |
| $1.00 |
VIP7Y
|
Career Henan Chemical Co
|
2019-12-24 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY